|
Reason for switch: n, %
| | | |
xx
|
|
Adverse event
|
11 (3)
|
0
|
11 (7)
| |
|
Ineffective/Disease Flare
|
202 (58)
|
202 (100)
|
0
| |
|
Infusion/Injection reaction
|
7 (2)
|
0
|
7 (5)
| |
|
Mild AE/Intolerance of Delivery mode
|
32 (9)
|
0
|
32 (22)
| |
|
other
|
66 (19)
|
0
|
66 (45)
| |
|
Unknown/Incomplete data
|
31 (9)
|
0
|
31 (21)
| |
|
Age (years) median, IQR
|
10 (7-13)
|
11 (8-13)
|
9 (6-13)
|
0.0099
|
|
Female (N, %)
|
274 (79)
|
157 (78)
|
117 (80)
|
ns
|
|
Time from start medication to switch (start 2nd) (days) median, IQR
|
394 (192-891)
|
306 (175-633)
|
660 (252-1233)
|
<0.0001
|
|
Elapsed time from discontinuation of 1st biologic to start of 2nd biologic (days) median, IQR
|
0 (0-21)
|
0 (0-7)
|
1 (0-80)
|
<0.0001
|
|
Calendar year of switch: median, range, IQR
|
2016 (2015-2017)
|
2016 (2015-2017)
|
2016 (2014-2017)
|
ns
|
|
Type of switch: n,%
| | | |
0.03
|
|
Etanercept to other TNF
|
221 (63)
|
130 (64)
|
91 (62)
| |
|
Etanercept to non TNF
|
33 (10)
|
19 (9)
|
14 (10)
| |
|
Other TNF to Etanercept
|
28 (8)
|
10 (5)
|
18 (12)
| |
|
Other TNF to non TNF
|
21 (6)
|
16 (8)
|
5 (3)
| |
|
Non TNF to Etanercept
|
7 (2)
|
1 (1)
|
6 (4)
| |
|
Non TNF to other TNF
|
4 (1)
|
3 (1.5)
|
1 (1)
| |
|
Non TNF to non TNF
|
5 (1)
|
3 (1.5)
|
2 (1)
| |
|
Other TNF to other TNF
|
30 (9)
|
20 (10)
|
10 (7)
| |
